Path Lab Holdings Inc history

The merger between National Health and Roche Biomedical was announced in December 1994.

Formation of LabCorp Through 1995 Merger

Acquires N.H. Company,” Greensboro News Record, March 27, 2001.

2002 LabCorp acquires Dynacare With the acquisition of Dynacare, LabCorp expands its geographic presence in the western and midwestern United States, as well as creating LabCorp’s first significant international presence in Canada.

In October 2003, PathLabs was acquired as a wholly-owned, self-sustaining subsidiary of Clinical Pathology Laboratories, Inc. (CPL), a large, highly successful, expanding independent medical laboratory headquartered in Austin, Texas.

2005 LabCorp acquires Esoterix, Inc. and US LABS Both Esoterix, Inc. and US LABS become part of the LabCorp family.

2006 Litholink becomes part of LabCorp LabCorp acquires Litholink, a leading provider of testing that provides targeted treatment information, helping physicians better manage and prevent chronic diseases, including kidney stones and chronic kidney disease.

2008 Tandem Laboratories purchased by LabCorp LabCorp expands its clinical trials, personalized medicine, and companion diagnostic capabilities by purchasing Tandem Laboratories.

2009 Monogram Biosciences is purchased by LabCorp LabCorp purchases Monogram Biosciences, a recognized leader in the discovery and commercialization of products to guide and improve the treatment of HIV, cancer, and other serious diseases.

2010 LabCorp finalizes acquisition of Genzyme Genetics LabCorp completes its $1 billion acquisition of Genzyme Genetics, a business unit of Genzyme Corporation.

2011 Orchid Cellmark, Inc. becomes part of LabCorp LabCorp acquires Orchid Cellmark, Inc. (Orchid), harmonizing two experienced and highly qualified forensics and family relationship laboratories.

2012 LabCorp acquires MEDTOX, forms three new subsidiaries 2012 is a big year for the LabCorp brand.

2014 Two new additions to LabCorp LabCorp acquires LipoScience, Inc., a provider of specialized cardiovascular diagnostic lab tests based on nuclear magnetic resonance (NMR) technology.

2015 Acquisition of Covance headlines a banner year In February 2015, LabCorp completes its $6 billion purchase of Covance, Inc., creating the world’s leading health care diagnostics company.

2017 LabCorp acquires Chiltern, PAML and Mount Sinai’s Clinical Outreach Laboratories Chiltern becomes part of the company’s Covance Drug Development business.

In October 2019, LabCorp celebrated its 50th anniversary and the company's transformation from a local laboratory operating in a former hospital to a leading global life sciences company that is deeply integrated in guiding patient care.